End-of-day quote
Korea S.E.
03:30:00 17/06/2024 am IST
|
5-day change
|
1st Jan Change
|
1,795
KRW
|
+0.39%
|
|
-4.32%
|
-31.75%
|
Fiscal Period: December |
2022
|
2023
|
---|
Capitalization
1 |
69,944
|
87,523
|
Enterprise Value (EV)
1 |
39,632
|
69,478
|
P/E ratio
|
-7.45
x
|
-8.95
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
6.94
x
|
12.6
x
|
EV / Revenue
|
3.93
x
|
9.97
x
|
EV / EBITDA
|
-4.91
x
|
-8.72
x
|
EV / FCF
|
-
|
-1,25,80,369
x
|
FCF Yield
|
-
|
-0%
|
Price to Book
|
1.62
x
|
2.54
x
|
Nbr of stocks (in thousands)
|
32,608
|
33,279
|
Reference price
2 |
2,145
|
2,630
|
Announcement Date
|
20/03/24
|
20/03/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net sales
1 |
10,083
|
6,967
|
EBITDA
1 |
-8,078
|
-7,969
|
EBIT
1 |
-9,676
|
-10,079
|
Operating Margin
|
-95.96%
|
-144.66%
|
Earnings before Tax (EBT)
1 |
-9,385
|
-9,684
|
Net income
1 |
-9,385
|
-9,684
|
Net margin
|
-93.07%
|
-139%
|
EPS
2 |
-287.8
|
-294.0
|
Free Cash Flow
|
-
|
-5,523
|
FCF margin
|
-
|
-79.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
20/03/24
|
20/03/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
Net Cash position
1 |
30,312
|
18,045
|
Leverage (Debt/EBITDA)
|
-
|
-
|
Free Cash Flow
|
-
|
-5,523
|
ROE (net income / shareholders' equity)
|
-
|
-24.9%
|
ROA (Net income/ Total Assets)
|
-
|
-14.6%
|
Assets
1 |
-
|
66,382
|
Book Value Per Share
2 |
1,327
|
1,036
|
Cash Flow per Share
2 |
698.0
|
355.0
|
Capex
1 |
1,909
|
3,174
|
Capex / Sales
|
18.93%
|
45.56%
|
Announcement Date
|
20/03/24
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -31.75% | 4.33Cr | | -44.13% | 762.66Cr | | +12.75% | 373.23Cr | | -0.62% | 226.1Cr | | -21.56% | 197.87Cr | | -22.28% | 163.45Cr | | +10.23% | 96Cr | | -5.90% | 72Cr | | -35.92% | 46Cr | | -3.18% | 28Cr |
Bio Diagnostics & Testing
|